AI, geopolitics, and new competitors are forcing Basel to fight harder for its place as a leading pharmaceutical hub.
The Roche towers on the right and the Novartis dome pavilion on the left.
Stefan Bohrer / Keystone
The Swiss city of Basel is still one of Europe’s great pharmaceutical centres, but AI, geopolitics, new competitors and changing investment patterns are forcing it to fight harder for its place in the industry.
Generated with artificial intelligence.
This content was published on
The pharma industry is a mainstay of the Swiss economy and a global heavyweight. But the rise of new players could shake things…
Swiss pharma companies warn current pricing rules delay access to new medicines.
Swiss pharma firms are boosting investment in North Carolina as tariffs and tax breaks reshape production plans.
Pharma manufacturing in Switzerland appears to be unperturbed by the threat of tariffs but it might take several years before the…
Interpharma warns Switzerland may face a US Section 301 trade probe targeting drug pricing, threatening $35.5 billion in pharma…
Swiss pharmaceutical firm Roche is investing billions in new obesity treatments in hopes of breaking into a highly competitive…
